Ruthigen starts patient enrolment in Phase I/II trial of RUT58-60
A total of 150 patients will be enrolled in the randomized, double-blind trial, which is designed to evaluate RUT58-60’s safety, tolerability and potential efficacy for use as an
GSK has entered an exclusive strategic partnership with SBP Group, via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to expedite the launch of bepirovirsen for chronic hepatitis B (CHB) patients in mainland China.
Under the agreement, MDD has the rights to market, sell and distribute Imprimis’ patent-pending Go Dropless™ formulations and other ophthalmic formulations in Puerto Rico. In addition, the agreement
K-Ras is the most commonly mutated oncogene in human cancers, with about 30% of all cancers harbouring activating ras mutations. Furthermore, cancers with a high prevalence of K-Ras